Rocket Pharma (NASDAQ: RCKT) is a fully-integrated, clinical-stage company advancing numerous gene therapies that could cure rare childhood diseases. Rocket places enormous value on people and takes team member progress and well-being just as seriously as the progress and well-being of its pipeline. We are looking for hands-on team players that enjoy collaborating with colleagues who share a passion for seeking gene therapy cures for devastating diseases and making a difference for patients. Become an integral part of a small, highly productive team and help grow an entrepreneurial, scientifically driven organization that is increasingly recognized as a leading biotechnology innovator. In addition to a competitive compensation package featuring a generous 401K match and stock options, positions include excellent health benefits.
For more information, please visit www.rocketpharma.com.
Twitter: https://bit.ly/2O28aHx
YouTube: https://bit.ly/3iNSXIu
For more information, please visit www.rocketpharma.com.
Twitter: https://bit.ly/2O28aHx
YouTube: https://bit.ly/3iNSXIu
Location: United States, New Jersey, Cranbury
Employees: 51-200
Phone: +1 646-440-9100
Founded date: 2015
Investors 5
| Date | Name | Website |
| 20.05.2025 | Avoro Capi... | avorocapit... |
| 11.01.2022 | Civilizati... | civilizati... |
| - | Frazier Li... | frazierls.... |
| - | Sahsen Ven... | sahsen.com |
| - | LifeSci Ve... | lifesciven... |
Mentions in press and media 7
| Date | Title | Description |
| 28.02.2025 | NYSE CONTENT ADVISORY: PRE-MARKET UPDATE + RARE DISEASE DAY AWARENESS | NEW YORK, Feb. 28, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) is proud to offer a daily pre-market update directly from the NYSE Trading Floor. Dr. Kinnari Patel, President, Head of R&D + COO at Rocket Pharma joins Trinity ... |
| 29.11.2024 | The Rise of Cerence: A New Contender in AI Voice Recognition | In the fast-paced world of artificial intelligence, Cerence (NASDAQ: CRNC) has emerged as a surprising player. The company, which specializes in AI virtual assistants for the automotive sector, has seen its stock soar by 155% in just two da... |
| 27.11.2024 | 3 Small-Cap Stocks That Are Ready to Rocket Higher With lower interest rates and lower corporate taxes more likely, it's a good time to consider three small-cap stocks that present a buying opportunit... | The Russell 2000 Index, often called the small-cap index, is up about 19.6% in 2024. Much of that gain has come in the last six months, and the clarity after the U.S. presidential election is stirring animal spirits in the sector. The bull... |
| 13.12.2021 | Rocket Pharmaceuticals Presents Positive Clinical Data from Company's Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual M... | Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces positive clinical updates from its ongoing Phase 2 reg... |
| 22.03.2021 | Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency | CRANBURY, N.J.--(BUSINESS WIRE)--Mar 22, 2021-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces update... |
| 09.03.2021 | Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I | CRANBURY, N.J.--(BUSINESS WIRE)--Mar 9, 2021-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that th... |
| - | Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results | CRANBURY, N.J.--(BUSINESS WIRE)--Feb 25, 2021-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financia... |